1)Richard SA, Sugaya N, Simonsen L, et al:A comparative study of the 1918-1920 influenza pandemic in Japan, USA and UK: mortality impact and implications for pandemic planning. Epidemiol Infect 137:1062-1072,2009
2)Sugaya N, Shinjoh M, Mitamura K, et al:Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect 63:288-294,2011
3)Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al:Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708-1719,2010
4)Muthuri SG, Venkatesan S, Myles PR, et al:Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2:395-404,2014
5)Beigel JH, Farrar J, Han AM, et al:Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-1385,2005
6)Watanabe T, Kiso M, Fukuyama S, et al:Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555,2013
7)Zhang Q, Shi J, Deng G, et al:H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341:410-414,2013
8)Gao HN, Lu HZ, Cao B, et al:Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 368:2277-2285,2013
9)Hu Y, Lu S, Song Z, et al:Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279,2013
10)日本感染症学会:提言「鳥インフルエンザA(H7N9)への対応【暫定】」,2013(http://www.kansensho.or.jp/influenza/1305_teigen.html)